{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T10:24:40Z","timestamp":1771237480827,"version":"3.50.1"},"reference-count":34,"publisher":"BMJ","issue":"12","funder":[{"DOI":"10.13039\/501100001215","name":"La Trobe University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001215","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Opioids and benzodiazepines are recommended to use for a short duration. Clinicians face a challenge to appraise the risk of new users to become long-term users. This study examined the pattern and probability of opioids and benzodiazepines dispensing among the new users.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>A unit-record data of an incident and a point-incident cohort of new users, who were not dispensed in the previous 2\u2009years, was examined and retrospectively followed up for 24\u2009months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>Australia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>A random 10% national sample.<\/jats:p><\/jats:sec><jats:sec><jats:title>Primary and secondary outcome measures<\/jats:title><jats:p>Distribution of total dispensing in calendar months. Probability of staying in the cohort in each successive month. Effect of first month\u2019s dispensing pattern on the total duration of dispensing during 2nd\u201324th month in total number of calendar months the dispensing was recorded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the incident cohort, 68.24% were dispensed opioids, 23.96% were dispensed benzodiazepines and 7.80% were dispensed both medicines. Over 70% in the incident cohort and 50% in the point-incident cohort were dispensed for a month only. Codeine was the most prevalent opioid, dispensed to 52% of opioid users; and diazepam was the most prevalent benzodiazepines, dispensed to 45.34% of benzodiazepine users. The probability of staying in the cohort and hence receiving further dispensing continued to be very high if dispensing did not end in the first month. The quantity (in defined daily dose) and the total number of dispensing episodes in the first month were significant predictors of the total duration of dispensing in the later period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Since harms from long-term use of these medicines may outweigh the benefits, and since the probability of further dispensing was high for those who were dispensed for more than a month, clinicians should endeavour to keep the dispensing duration and quantity as small as possible while initiating a prescription for the new users.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2019-030803","type":"journal-article","created":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T10:05:15Z","timestamp":1577786715000},"page":"e030803","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Pattern and probability of dispensing of prescription opioids and benzodiazepines among the new users in Australia: a retrospective cohort study"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1330-863X","authenticated-orcid":false,"given":"M Mofizul","family":"Islam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,12,30]]},"reference":[{"key":"2020050713450071000_9.12.e030803.1","first-page":"862","article-title":"Prescription drug abuse \u2013 a timely update","volume":"45","author":"Monheit","year":"2016","journal-title":"Substance Use"},{"key":"2020050713450071000_9.12.e030803.2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2711-15.2015"},{"key":"2020050713450071000_9.12.e030803.3","doi-asserted-by":"publisher","DOI":"10.1080\/15622970802465807"},{"key":"2020050713450071000_9.12.e030803.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04418.x"},{"key":"2020050713450071000_9.12.e030803.5","doi-asserted-by":"crossref","unstructured":"Baldini A , Von Korff M , Lin EHB . A review of potential adverse effects of long-term opioid therapy: a practitioner's guide. Prim Care Companion CNS Disord 2012;14.doi:10.4088\/PCC.11m01326","DOI":"10.4088\/PCC.11m01326"},{"key":"2020050713450071000_9.12.e030803.6","first-page":"98","article-title":"Opioid use in chronic non-cancer pain--part 1: known knowns and known unknowns","volume":"42","author":"Holliday","year":"2013","journal-title":"Aust Fam Physician"},{"key":"2020050713450071000_9.12.e030803.7","first-page":"982","article-title":"Weighing the risks and benefits of chronic opioid therapy","volume":"93","author":"Lembke","year":"2016","journal-title":"Am Fam Physician"},{"key":"2020050713450071000_9.12.e030803.8","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/10826084.2017.1305415","article-title":"Prescription opioid misuse and public health approach in Australia","volume":"53","author":"Kovitwanichkanont","year":"2018","journal-title":"Subst Use Misuse"},{"key":"2020050713450071000_9.12.e030803.9","doi-asserted-by":"crossref","unstructured":"Islam M , Wollersheim D . Who are dispensed the bulk amount of prescription opioids? J Clin Med 2019;8.doi:10.3390\/jcm8030293","DOI":"10.3390\/jcm8030293"},{"key":"2020050713450071000_9.12.e030803.10","unstructured":"Public Health Association Australia . Opioids and benzodiazepines dispensing from community-pharmacies in Australia: trends and prevention efforts, 2019. Available: https:\/\/www.prevention2019.com\/program"},{"key":"2020050713450071000_9.12.e030803.11","doi-asserted-by":"publisher","DOI":"10.7326\/M17-1408"},{"key":"2020050713450071000_9.12.e030803.12","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp17X691865"},{"key":"2020050713450071000_9.12.e030803.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1465-3362.2010.00271.x"},{"key":"2020050713450071000_9.12.e030803.14","doi-asserted-by":"crossref","unstructured":"Mellish L , Karanges EA , Litchfield MJ , et al . The Australian pharmaceutical benefits scheme data collection: a practical guide for researchers. BMC Res Notes 2015;8:634.doi:10.1186\/s13104-015-1616-8","DOI":"10.1186\/s13104-015-1616-8"},{"key":"2020050713450071000_9.12.e030803.15","unstructured":"NPS Medicinewise . How do I get the pharmaceutical benefits scheme (PBS) subsidy? 2019. Available: https:\/\/www.nps.org.au\/consumers\/keeping-your-medicines-costs-down#what-will-a-medicine-on-the-pbs-cost-me?%C2%A0; [Accessed 28 Jun 2019]."},{"key":"2020050713450071000_9.12.e030803.16","unstructured":"World Health Organization . Guidelines for ATC classification and DDD assignment. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 2017. https:\/\/www.whocc.no\/filearchive\/publications\/2017_guidelines_web.pdf"},{"key":"2020050713450071000_9.12.e030803.17","doi-asserted-by":"crossref","unstructured":"Silva J , Tenreyro S . The Log of Gravity Review of Economics and Statistics 2006;88:641\u201358.","DOI":"10.1162\/rest.88.4.641"},{"key":"2020050713450071000_9.12.e030803.18","unstructured":"The Stata Blog . Use Poisson rather than REGRESS; tell a Friend, 2010. Available: https:\/\/blog.stata.com\/2011\/08\/22\/use-poisson-rather-than-regress-tell-a-friend\/"},{"key":"2020050713450071000_9.12.e030803.19","unstructured":"StataCorp . Stata statistical software: release 14. College Station, TX: StataCorp LP, 2015."},{"key":"2020050713450071000_9.12.e030803.20","unstructured":"Microsoft . Microsoft Excel [computer software. Redmond, Washington: Microsoft, 2013."},{"key":"2020050713450071000_9.12.e030803.21","doi-asserted-by":"publisher","DOI":"10.1038\/nature08758"},{"key":"2020050713450071000_9.12.e030803.22","doi-asserted-by":"publisher","DOI":"10.1151\/spp021113"},{"key":"2020050713450071000_9.12.e030803.23","doi-asserted-by":"publisher","DOI":"10.1097\/01.j.pain.0000460357.01998.f1"},{"key":"2020050713450071000_9.12.e030803.24","doi-asserted-by":"crossref","unstructured":"Sun EC , Dixit A , Humphreys K , et al . Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ 2017;356.doi:10.1136\/bmj.j760","DOI":"10.1136\/bmj.j760"},{"key":"2020050713450071000_9.12.e030803.25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/829696","article-title":"Factors associated with opioid use in a cohort of patients presenting for surgery","volume":"2015","author":"Hah","year":"2015","journal-title":"Pain Res Treat"},{"key":"2020050713450071000_9.12.e030803.26","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2011.1827"},{"key":"2020050713450071000_9.12.e030803.27","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1001\/jamainternmed.2018.2413","article-title":"Factors associated with long-term benzodiazepine use among older adults","volume":"178","author":"Gerlach","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2020050713450071000_9.12.e030803.28","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2174\/1573400510666140320000928","article-title":"Genetics of opioid dependence: a review of the genetic contribution to opioid dependence","volume":"10","author":"Mistry","year":"2014","journal-title":"Curr Psychiatry Rev"},{"key":"2020050713450071000_9.12.e030803.29"},{"key":"2020050713450071000_9.12.e030803.30","unstructured":"Woodley M . Codeine supply in Australia has almost halved. Available: https:\/\/www1.racgp.org.au\/newsgp\/clinical\/codeine-supply-in-australia-has-almost-halved [Accessed 19 Jul 2019]."},{"key":"2020050713450071000_9.12.e030803.31","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1111\/add.13450","article-title":"The impact of codeine re-scheduling on misuse: a retrospective review of calls to Australia's largest poisons centre","volume":"111","author":"Cairns","year":"2016","journal-title":"Addiction"},{"key":"2020050713450071000_9.12.e030803.32","doi-asserted-by":"crossref","first-page":"79","DOI":"10.18773\/austprescr.2014.033","article-title":"Pharmaceutical drug misuse in Australia","volume":"37","author":"Dobbin","year":"2014","journal-title":"Aust Prescr"},{"key":"2020050713450071000_9.12.e030803.33","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2015.1673"},{"key":"2020050713450071000_9.12.e030803.34","doi-asserted-by":"crossref","unstructured":"Ogeil RP , Heilbronn C , Lloyd B , et al . Prescription drug monitoring in Australia: capacity and coverage issues. Med J Aust 2016;204.doi:10.5694\/mja15.00929","DOI":"10.5694\/mja15.00929"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-030803","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T02:01:40Z","timestamp":1601085700000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-030803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":34,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12,17]]},"published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1136\/bmjopen-2019-030803"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-030803","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}